Key Points
- Director Arnold Baskies purchased 5,000 Anixa Biosciences shares at an average price of $2.76, investing $13,800 and increasing his ownership by 3.69% to 140,572 shares.
- ANIX opened at $2.79, with a 52-week range of $2.32 to $5.46 and a market capitalization of approximately $96.98 million. The company reported quarterly EPS of negative $0.08, in line with analyst expectations.
- Analyst sentiment is mixed, with three Buy, one Hold, and one Sell rating; the average rating is Hold, while the average price target is $8.00. Institutional investors and hedge funds own 29.13% of the stock.
Anixa Biosciences Inc (NASDAQ:ANIX - Get Free Report) Director Arnold Baskies bought 5,000 shares of the company's stock in a transaction dated Thursday, September 24th. The stock was purchased at an average cost of $2.76 per share, for a total transaction of $13,800.00. Following the completion of the transaction, the director owned 140,572 shares of the company's stock, valued at $387,978.72. This represents a 3.69% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Anixa Biosciences Price Performance
ANIX stock opened at $2.79 on Tuesday. Anixa Biosciences Inc has a 52-week low of $2.32 and a 52-week high of $5.46. The company's 50 day simple moving average is $3.23 and its 200-day simple moving average is $2.97. The firm has a market capitalization of $96.98 million, a P/E ratio of -8.72 and a beta of 0.51.
Anixa Biosciences (NASDAQ:ANIX - Get Free Report) last issued its quarterly earnings results on Wednesday, September 9th. The company reported ($0.08) EPS for the quarter, meeting the consensus estimate of ($0.08). Sell-side analysts predict that Anixa Biosciences Inc will post -0.31 EPS for the current fiscal year.
Analysts Set New Price Targets
A number of brokerages have recently weighed in on ANIX. Citigroup reiterated a "buy" rating on shares of Anixa Biosciences in a report on Friday, June 12th. Wall Street Zen raised Anixa Biosciences from a "sell" rating to a "hold" rating in a research note on Saturday, June 20th. Weiss Ratings upgraded Anixa Biosciences from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Thursday, September 17th. Zacks Research cut Anixa Biosciences from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, August 19th. Finally, D. Boral Capital reiterated a "buy" rating and issued a $10.00 target price on shares of Anixa Biosciences in a report on Tuesday, June 30th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Hold" and an average price target of $8.00.
View Our Latest Research Report on Anixa Biosciences
Institutional Investors Weigh In On Anixa Biosciences
A number of institutional investors have recently modified their holdings of the stock. BlackRock Inc. purchased a new position in shares of Anixa Biosciences during the 2nd quarter valued at $559,000. GSA Capital Partners LLP acquired a new position in shares of Anixa Biosciences in the second quarter worth $329,000. Renaissance Technologies LLC raised its holdings in shares of Anixa Biosciences by 13.6% during the first quarter. Renaissance Technologies LLC now owns 61,173 shares of the company's stock worth $158,000 after acquiring an additional 7,300 shares in the last quarter. Kestra Advisory Services LLC raised its holdings in shares of Anixa Biosciences by 96.2% during the first quarter. Kestra Advisory Services LLC now owns 51,000 shares of the company's stock worth $132,000 after acquiring an additional 25,000 shares in the last quarter. Finally, Bank of New York Mellon Corp acquired a new stake in Anixa Biosciences during the second quarter valued at $133,000. Institutional investors and hedge funds own 29.13% of the company's stock.
About Anixa Biosciences
(
Get Free Report)
Anixa Biosciences, Inc is a clinical-stage biotechnology company focused on developing immunotherapies and vaccines for cancer and infectious diseases. The company's research programs are designed to use the immune system to prevent or treat serious illnesses.
Anixa's cancer programs include vaccine approaches for ovarian cancer and triple-negative breast cancer, developed in collaboration with researchers at Cleveland Clinic. The company is also developing chimeric antigen receptor T-cell, or CAR-T, therapies intended to target cancer cells, including programs focused on ovarian cancer.
In addition to oncology, Anixa has pursued vaccine and therapeutic technologies for infectious diseases.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
